



NEXT GENERATION COMPANION DIAGNOSTICS CONFERENCE

*Aiding the process of personalized treatment:
increasing safety and efficacy of drugs*

13th - 14th July 2017, Philadelphia, USA

Event Overview

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought to light issues regarding regulations and their intricacies and boosted news trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

MarketsandMarkets is pleased to announce '**The Next Generation Companion Diagnostics Conference**' on **13th – 14th July, 2017 in Philadelphia, USA** which will congregate experts from the field of personalized medicine and precision medicine from pharmaceutical and academic institutes and understand the emerging trends and challenges from their perspective.

Key Highlights

- Multiplex Companion Diagnostics
- Commercialization of CDx
- Design of clinical trials in CDx
- Relevant Biomarkers in CDx
- Immuno-Oncology
- Immunotherapy
- CDx Regulatory guidelines

Who should attend?


From pharmaceutical, academics, biotechnology companies and laboratories

Chief Scientific Officers/Heads/VPs/Directors/ Project Heads in:

- ▶ Companion Diagnostics
- ▶ Personalized Medicine
- ▶ Precision Medicine
- ▶ Pathology and Laboratory Medicine
- ▶ Bioinformatics
- ▶ Biostatistics
- ▶ R&D

Why attend?

- ▶ Contribute to the various experiences in **co-developing** companion diagnostic tools
- ▶ Understand the perspective of pharma companies regarding CDx
- ▶ Explore about **data mining** in CDx and best practices to interpret data for **right treatment options**
- ▶ Learn more about CDx **regulatory affairs**
- ▶ Network with peers and share ideas.



NEXT GENERATION COMPANION DIAGNOSTICS CONFERENCE

Aiding the process of personalized treatment: increasing safety and efficacy of drugs

13th - 14th July 2017, Philadelphia, USA

Day 1, 13th July 2017

08:15 Registration

08:55 Welcome note from MarketsandMarkets

09:00 Opening Remarks from the Chairman

MULTIPLEX COMPANION DIAGNOSTICS

09:10 Keynote Presentation: **The need and development of multiplex companion diagnostics**

09:35 **Overcoming technical hurdles of sensitivity to perform copy no. variations and gene expression profiling in liquid biopsy**

10:00 **Solution Provider Presentation; Please contact Steve Hambrook at steve.h@marketsandmarkets.com**

10:30 *Morning Refreshments and Poster Presentation | One-to-One Networking Meetings*

11:20 **Transition to commercially viable platforms to detect multiple targets for CDx**

11:45 **Solution Provider Presentation; Please contact Steve Hambrook at steve.h@marketsandmarkets.com**

12:15 **Multi-therapy approach in CDx**

12:40 **Solution Provider Presentation; Please contact Steve Hambrook at steve.h@marketsandmarkets.com**

12:55 **A well-founded partnership with the right partners to develop a successful CDx**

- Challenges faced by Pharmaceutical companies to develop CDx platforms
- Collaborations by diagnostics and pharmaceutical companies: Quality compliance in Diagnostic tools
- Operations in biotechnology companies to develop robust assays for accurate results

Panel
Discussion

13:25 *Lunch and Poster Presentation | One-to-One Networking Meetings*

EMERGING TRENDS IN CDx: IMMUNOTHERAPY & IMMUNONCOLOGY

14:25 **Importance of check point inhibitors in immunotherapy based CDx**

14:50 **Solution Provider Presentation; Please contact Steve Hambrook at steve.h@marketsandmarkets.com**

15:05 **Minimal residual disease: developing sensitive assays for CDx**

15:30 **Role and significance of driver mutation in cancers to develop CDx**

15:55 *Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings*

DESIGN OF CLINICAL DESIGN TRIALS IN CDx

16:45 **Designing clinical trials optimized for precision medicine**


17:10 **Development of standardized processes for smoother clinical trials in CDx**

17:35 **Interpreting multivariate gene clinical test results in CDx**

18:00 **Closing Remarks from the Chairman**

18:05 **Drinks Reception & Networking**

End of Day 1



NEXT GENERATION COMPANION DIAGNOSTICS CONFERENCE

Aiding the process of personalized treatment: increasing safety and efficacy of drugs

13th - 14th July 2017, Philadelphia, USA

Day 2, 14th July 2017

08:15 Registration

08:55 Welcome note from MarketsandMarkets

09:00 Opening Remarks from the Chairman

REGULATORY, REIMBURSEMENT AND COST IN CDx

09:10 Keynote: **Assessing lab developed test to achieve standardization in CDx**

09:35 Trends in costs and reimbursement for the use of CDx

10:00 **Solution Provider Presentation; Please contact Steve Hambrook at steve.h@marketsandmarkets.com**

10:30 *Morning Refreshments and Poster Presentation | One-to-One Networking Meetings*

IDENTIFICATION OF RELEVANT BIOMARKERS IN CDx

11:20 Predicting efficacy of the drug using relevant and strong biomarkers

11:45 **Solution Provider Presentation; Please contact Steve Hambrook at steve.h@marketsandmarkets.com**

12:00 Emerging trends in blood based biomarkers in CDx

12:25 Combination of biomarkers to find a better response to a drug

12:50 **International harmonization of biomarkers used in CDx**

- Challenges faced in finding relevant biomarkers
- Assessing safety and efficacy of the drug by linking it to the relevant biomarker
- Effects on Reimbursement policies

Panel
Discussion

13:20 *Lunch and Poster Presentation | One-to-One Networking Meetings*

STATISTICS AND DATA IN CDx

14:20 Finding relevant data sets to develop CDx tests

14:45 Developing algorithms for NGS data to find biomarkers for CDx

15:10 Data mining in CDx to arrive at personalized treatment regimens

15:35 Use of CDx data to link the right drug to the treatment

16:00 Closing remarks from Chairman

End of Conference